JP2016536012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536012A5 JP2016536012A5 JP2016549206A JP2016549206A JP2016536012A5 JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5 JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5
- Authority
- JP
- Japan
- Prior art keywords
- pkal
- inhibitor
- assay
- subject
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 20
- 239000003112 inhibitor Substances 0.000 claims 13
- 102000002261 High-Molecular-Weight Kininogen Human genes 0.000 claims 11
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 11
- 238000003556 assay Methods 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000012190 activator Substances 0.000 claims 5
- 239000000758 substrate Substances 0.000 claims 5
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 4
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 238000001262 western blot Methods 0.000 claims 3
- 238000001994 activation Methods 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 108010071241 Factor XIIa Proteins 0.000 claims 1
- 238000010228 ex vivo assay Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000678 plasma activation Methods 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893505P | 2013-10-21 | 2013-10-21 | |
| US61/893,505 | 2013-10-21 | ||
| US201461939837P | 2014-02-14 | 2014-02-14 | |
| US61/939,837 | 2014-02-14 | ||
| PCT/US2014/061247 WO2015061183A1 (en) | 2013-10-21 | 2014-10-17 | Assays for determining plasma kallikrein system biomarkers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144118A Division JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536012A JP2016536012A (ja) | 2016-11-24 |
| JP2016536012A5 true JP2016536012A5 (enExample) | 2017-11-24 |
| JP6757252B2 JP6757252B2 (ja) | 2020-09-16 |
Family
ID=52993413
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549206A Active JP6757252B2 (ja) | 2013-10-21 | 2014-10-17 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2022137393A Active JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2024117419A Pending JP2024150637A (ja) | 2013-10-21 | 2024-07-23 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2022137393A Active JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2024117419A Pending JP2024150637A (ja) | 2013-10-21 | 2024-07-23 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11372002B2 (enExample) |
| EP (2) | EP3060582B1 (enExample) |
| JP (4) | JP6757252B2 (enExample) |
| KR (4) | KR20250066486A (enExample) |
| CN (1) | CN105873951A (enExample) |
| AU (3) | AU2014340450B2 (enExample) |
| BR (1) | BR112016008970B1 (enExample) |
| CA (1) | CA2927824C (enExample) |
| DK (1) | DK3060582T3 (enExample) |
| ES (1) | ES2837858T3 (enExample) |
| IL (3) | IL289514B2 (enExample) |
| PL (1) | PL3060582T3 (enExample) |
| WO (1) | WO2015061183A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011204349C1 (en) | 2010-01-06 | 2017-02-16 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| WO2012094587A1 (en) * | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| IL273688B2 (en) * | 2013-01-20 | 2024-12-01 | Dyax Corp | Evaluation and treatment of bradykinin-mediated disorders |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| WO2015061182A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| ES2856076T3 (es) | 2014-01-21 | 2021-09-27 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| AU2016243160B2 (en) * | 2015-03-30 | 2022-02-24 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| BR112018002742B1 (pt) * | 2015-08-13 | 2023-05-16 | Takeda Pharmaceutical Company Limited | Tubo de coleta de sangue evacuado, método para a avaliação do nível endógeno de ativação do sistema de contato em um sujeito, método para a avaliação do nível de um fármaco visando o sistema de contato em um sujeito e método para a avaliação da imunogenicidade de um fármaco visando o sistema de contato |
| WO2017070170A1 (en) * | 2015-10-19 | 2017-04-27 | Dyax Corp. | Immunoassay to detect cleaved high molecular weight kininogen |
| IL312919B1 (en) * | 2015-12-15 | 2025-10-01 | Takeda Pharmaceuticals Co | Peptide assay to distinguish between full-length high molecular weight kinogen (HMWK) and cleaved HMWK |
| BR112019005172A2 (pt) * | 2016-09-16 | 2019-07-02 | Dyax Corp. | método e kit para analisar uma amostra |
| MX2019002932A (es) * | 2016-09-16 | 2019-07-15 | Dyax Corp | Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto. |
| EP3513197A1 (en) * | 2016-09-16 | 2019-07-24 | Dyax Corp. | Metabolite biomarkers for diseases associated with the contact activation system |
| EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
| US20200407771A1 (en) * | 2018-02-22 | 2020-12-31 | The Regents Of The University Of California | Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema |
| CN111057745B (zh) * | 2019-12-30 | 2022-08-12 | 中国科学院生态环境研究中心 | 一种物质的血液毒性效应的高通量筛选方法 |
| EP4126219A2 (en) * | 2020-04-04 | 2023-02-08 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| CN113777331A (zh) * | 2020-06-09 | 2021-12-10 | 张曼 | 尿液激肽原-1及其多肽片段在烧伤中的应用 |
| CN114166924B (zh) * | 2021-12-03 | 2024-11-22 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
| EP4548103A2 (en) * | 2022-06-30 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
| WO2025153806A1 (en) * | 2024-01-15 | 2025-07-24 | Kalvista Pharmaceuticals Limited | Methods for determining amidolytic activity |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1312564C (en) * | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPS63185398A (ja) * | 1986-09-10 | 1988-07-30 | Nippon Zoki Pharmaceut Co Ltd | 生理活性物質測定法 |
| US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5472945A (en) | 1991-08-13 | 1995-12-05 | Temple University- Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| EP0739355B1 (en) | 1994-01-11 | 2004-09-08 | Dyax Corporation | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| JPH1084995A (ja) | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第ｘｉｉ因子活性化法 |
| US5789261A (en) | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
| US6242210B1 (en) * | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| JP4346798B2 (ja) | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US7067713B2 (en) * | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| JP2002221519A (ja) | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US6913900B2 (en) * | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| US7064107B2 (en) | 2002-06-07 | 2006-06-20 | Dyax Corp. | Prevention and reduction of blood loss |
| WO2004005934A2 (en) | 2002-07-04 | 2004-01-15 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1598428A1 (en) * | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| AU2006332774A1 (en) | 2005-12-29 | 2007-07-12 | Dyax Corp. | Protease inhibition |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| US7625944B2 (en) | 2006-07-31 | 2009-12-01 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| EP2089712A4 (en) | 2006-11-22 | 2010-09-22 | Life Technologies Corp | BIOMARKERS OF AUTOIMMUNE DISEASES |
| US20090075887A1 (en) | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
| US8263347B2 (en) | 2007-10-18 | 2012-09-11 | Miyazaki Prefectural Industrial Support Foundation | Biomarker for diagnosis of liver disease |
| CA2703264A1 (en) * | 2007-10-22 | 2009-04-30 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| WO2010004962A1 (ja) | 2008-07-07 | 2010-01-14 | 日本臓器製薬株式会社 | 線維筋痛症の検査法 |
| US20110212104A1 (en) | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| WO2010065656A1 (en) | 2008-12-02 | 2010-06-10 | Joslin Diabetes Center | Method for reducing blood pressure using inhibitors of plasma kallikrein |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| FR2942233B1 (fr) | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
| KR101077275B1 (ko) | 2009-05-07 | 2011-10-27 | 한국기초과학지원연구원 | 당단백질의 당쇄화를 이용한 암 진단 방법 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| KR20120120237A (ko) | 2009-12-18 | 2012-11-01 | 액티브사이트 파마슈티칼즈, 인크. | 혈장 칼리크레인 억제제의 전구약물 |
| AU2011204349C1 (en) | 2010-01-06 | 2017-02-16 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| EP2593121A2 (en) | 2010-07-13 | 2013-05-22 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| CN103384496B (zh) | 2010-12-02 | 2016-10-12 | 贝克顿·迪金森公司 | 含有血液稳定剂的血液收集装置 |
| WO2012094587A1 (en) * | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| WO2012170945A2 (en) * | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
| FR2983215B1 (fr) * | 2011-11-28 | 2013-12-20 | Univ Grenoble 1 | Dosage de la capacite de controle de c1inh |
| IL273688B2 (en) | 2013-01-20 | 2024-12-01 | Dyax Corp | Evaluation and treatment of bradykinin-mediated disorders |
| AU2014212194A1 (en) | 2013-02-01 | 2015-09-17 | Becton, Dickinson And Company | Blood collection devices containing contact pathway inhibition additives |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| WO2015061182A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| ES2856076T3 (es) | 2014-01-21 | 2021-09-27 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario |
| WO2017070170A1 (en) | 2015-10-19 | 2017-04-27 | Dyax Corp. | Immunoassay to detect cleaved high molecular weight kininogen |
| IL312919B1 (en) | 2015-12-15 | 2025-10-01 | Takeda Pharmaceuticals Co | Peptide assay to distinguish between full-length high molecular weight kinogen (HMWK) and cleaved HMWK |
| EP4096687A4 (en) | 2020-01-28 | 2024-02-28 | Orgenesis Inc. | Process and system for acellular therapy |
-
2014
- 2014-10-17 KR KR1020257014548A patent/KR20250066486A/ko active Pending
- 2014-10-17 WO PCT/US2014/061247 patent/WO2015061183A1/en not_active Ceased
- 2014-10-17 CA CA2927824A patent/CA2927824C/en active Active
- 2014-10-17 KR KR1020167013432A patent/KR102432826B1/ko active Active
- 2014-10-17 KR KR1020237012295A patent/KR20230054745A/ko not_active Ceased
- 2014-10-17 IL IL289514A patent/IL289514B2/en unknown
- 2014-10-17 DK DK14856778.7T patent/DK3060582T3/da active
- 2014-10-17 ES ES14856778T patent/ES2837858T3/es active Active
- 2014-10-17 EP EP14856778.7A patent/EP3060582B1/en active Active
- 2014-10-17 EP EP20197583.6A patent/EP3808857B1/en active Active
- 2014-10-17 JP JP2016549206A patent/JP6757252B2/ja active Active
- 2014-10-17 KR KR1020227027698A patent/KR102521947B1/ko active Active
- 2014-10-17 BR BR112016008970-7A patent/BR112016008970B1/pt active IP Right Grant
- 2014-10-17 US US15/030,811 patent/US11372002B2/en active Active
- 2014-10-17 CN CN201480070281.6A patent/CN105873951A/zh active Pending
- 2014-10-17 PL PL14856778T patent/PL3060582T3/pl unknown
- 2014-10-17 AU AU2014340450A patent/AU2014340450B2/en active Active
-
2016
- 2016-04-19 IL IL245205A patent/IL245205B/en active IP Right Grant
-
2020
- 2020-04-19 IL IL274055A patent/IL274055B/en unknown
- 2020-08-10 AU AU2020217316A patent/AU2020217316B2/en active Active
- 2020-08-28 JP JP2020144118A patent/JP7135039B2/ja active Active
-
2021
- 2021-12-20 US US17/555,636 patent/US12442824B2/en active Active
-
2022
- 2022-08-31 JP JP2022137393A patent/JP7668772B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203355A patent/AU2024203355A1/en active Pending
- 2024-07-23 JP JP2024117419A patent/JP2024150637A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536012A5 (enExample) | ||
| Ouyang et al. | Dysregulated serum MiRNA profile and promising biomarkers in dengue-infected patients | |
| Huang et al. | Urinary Xist is a potential biomarker for membranous nephropathy | |
| Duvoix et al. | Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease | |
| Xu et al. | Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell | |
| Liao et al. | Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma | |
| JP2017503488A5 (enExample) | ||
| Ye et al. | The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma | |
| WO2014140933A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| Li et al. | MiR-217 is involved in the carcinogenesis of gastric cancer by down-regulating CDH1 expression | |
| JP2017500584A5 (enExample) | ||
| BRPI1008957B8 (pt) | método para detecção simultânea de uma pluralidade de ácidos nucleicos alvo executado por um sistema de análise integrada em tempo real de ácidos nucleicos alvo | |
| Kovalenko et al. | ROS production, intracellular HSP70 levels and their relationship in human neutrophils: effects of age | |
| US10895572B2 (en) | Autophagy-related nourin gene-based RNA network as early biomarkers for cardiac patients | |
| BR112016019740A2 (pt) | monitoramento do estado de inflamação | |
| JP2017514813A5 (enExample) | ||
| JP2015523569A5 (enExample) | ||
| CN106544342B (zh) | Mt2a基因组蛋白乙酰化修饰检测试剂盒及引物对 | |
| US20210214793A1 (en) | Blood biomarkers of stroke | |
| Ramsay et al. | Blood transcriptomic biomarker as a surrogate of ischemic brain gene expression | |
| Solheim et al. | Prothrombotic markers in patients with acute myocardial infarction and left ventricular thrombus formation treated with pci and dual antiplatelet therapy | |
| Shen et al. | Screening of differentially expressed genes related to severe sepsis induced by multiple trauma with DNA microarray. | |
| WO2015121737A4 (en) | Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure | |
| Tahoun et al. | Deregulated expression of autophagy genes; PIK3C3 and RAB7A in COVID-19 patients | |
| Chen et al. | A single nucleotide polymorphism located in microRNA-499a causes loss of function resulting in increased expression of osbpl1a and reduced serum HDL level |